Eupraxia Pharmaceuticals (EPRX) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Eupraxia Pharmaceuticals (NASDAQ: EPRX):

• 10/20/2026 – Eupraxia Pharmaceuticals had its “outperform” rating reaffirmed by Oppenheimer.
• 10/17/2026 – Eupraxia Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/15/2026 – Eupraxia Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/8/2026 – Eupraxia Pharmaceuticals had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/1/2026 – Eupraxia Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $11.00 price target on the stock.
• 9/24/2026 – Eupraxia Pharmaceuticals was given a new $25.00 price target by Stifel Nicolaus.
• 9/24/2026 – Eupraxia Pharmaceuticals is now covered by Wedbush. They set an “outperform” rating and a $17.00 price target on the stock.
• 9/12/2026 – Eupraxia Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.